
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| RASUVO | Medexus Pharmaceuticals | N-205776 RX | 2014-07-10 | 9 products, RLD, RS |
| JYLAMVO | Shorla Pharma | N-212479 RX | 2022-11-29 | 1 products, RLD, RS |
Brand Name | Status | Last Update |
|---|---|---|
| jylamvo | New Drug Application | 2025-04-28 |
| methotrexate | ANDA | 2025-09-15 |
| methotrexate sodium | ANDA | 2024-03-01 |
| otrexup | New Drug Application | 2025-01-31 |
| rasuvo | New Drug Application | 2024-12-06 |
| trexall | ANDA | 2021-04-30 |
| xatmep | New Drug Application | 2022-06-28 |
Expiration | Code | ||
|---|---|---|---|
METHOTREXATE SODIUM, XATMEP, AZURITY | |||
| 2024-04-25 | ODE-137, ODE-138 | ||
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Methotrexate Sodium, Xatmep, Azurity | |||
| 9259427 | 2033-01-02 | DP | |
| 9855215 | 2033-01-02 | DP | |
| 10231927 | 2033-01-02 | U-1349, U-1699 | |
| 10610485 | 2033-01-02 | DP | |
| 11116724 | 2033-01-02 | U-1349, U-1699 | |
| Methotrexate, Otrexup, Otter Pharms | |||
| 8814834 | 2031-05-27 | DP | |
| 8480631 | 2030-03-19 | DP | U-1442 |
| 8579865 | 2030-03-19 | DP | U-1442 |
| 8945063 | 2030-03-19 | DP | U-1442 |
| 9421333 | 2030-03-19 | DP | U-1442 |
| 11497753 | 2030-03-19 | DP | |
| 9867949 | 2029-03-10 | DP | |
| 10709844 | 2029-03-10 | DP | |
| 8021335 | 2026-10-04 | DP | |
| 8562564 | 2026-01-24 | DP | |
| 9533102 | 2026-01-24 | DP | |
| 9629959 | 2026-01-24 | DP | |
| 11446441 | 2026-01-24 | DP | |
| Methotrexate, Rasuvo, Medexus | |||
| 8664231 | 2029-06-01 | U-1442 | |

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | — | — | — | 1 | — | 1 |
| Arthritis | D001168 | EFO_0005856 | M05-M14 | — | — | — | 1 | — | 1 |
| Drug common name | Methotrexate |
| INN | methotrexate |
| Description | Methotrexate is a member of pteridines, a monocarboxylic acid amide and a dicarboxylic acid. It has a role as an antineoplastic agent, an antirheumatic drug, an EC 1.5.1.3 (dihydrofolate reductase) inhibitor, a DNA synthesis inhibitor, an abortifacient, a dermatologic drug, an antimetabolite and an immunosuppressive agent. It is functionally related to a L-glutamic acid. It is a conjugate acid of a methotrexate(1-). |
| Classification | Small molecule |
| Drug class | antimetabolites (folic acid derivatives) |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1 |
| PDB | — |
| CAS-ID | 59-05-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL34259 |
| ChEBI ID | 44185 |
| PubChem CID | 126941 |
| DrugBank | DB00563 |
| UNII ID | YL5FZ2Y5U1 (ChemIDplus, GSRS) |












